Vetoryl, Trilostane, Canine Cushing's Disease
Vetoryl or Trilostane is an adrenocortical suppressant for oral use in dogs only and is used for the treatment of hyperadrenocorticism, also known as Cushing's Disease. Cushing's Disease is a condition where too much of the hormone cortisol is produced.Add this item to your cart:
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.
What is Cushing's Syndrome?:
Vetoryl, Trilostane, Canine Cushing's Disease
DOSAGE AND ADMINISTRATION:
Always completely read the Client Information Sheet with prescription.
The starting dose for the treatment of hyperadrenocorticism in dogs is 1.0-3.0 mg/lb 2.2-6.7 mg/kg once a day based on body weight and capsule size. Follow your Veterinarians prescription dosage that will be dependent on the weight of your pet.
VETORYL Capsules should be administered with food.
Individual dose adjustments and close monitoring are essential.
Your Veterinarian will Re-examine and conduct an ACTH stimulation test 10-14 days after every dose alteration. Care must be taken during dose increases to monitor the dog's clinical signs and serum electrolyte concentrations. Once daily administration is recommended. However, if clinical signs are not controlled for the full day, twice daily dosing may be needed. To switch from once daily to twice daily dosing, increase the total daily dose by 1/3 to 1/2 and divide the total amount into two doses given 12 hours apart.
Once an optimum dose of VETORYL Capsules has been reached, re-examine the dog at 30 days, 90 days and every 3 months thereafter. At a minimum, this monitoring should include a thorough history and physical examination, ACTH stimulation test conducted 4-6 hours after VETORYL Capsule administration, and serum biochemical tests with particular attention to electrolytes, renal and hepatic function. Good control is indicated by favorable clinical signs as well as post-ACTH serum cortisol of 1.45-9.1 &mug/dL 40-250 nmol/L.
The use of VETORYL Capsules is contraindicated in dogs that have demonstrated hypersensitivity to trilostane. Do not use VETORYL Capsules in animals with primary hepatic disease or renal insufficiency. Do not use in pregnant dogs. Studies conducted with trilostane in laboratory animals have shown teratogenic effects and early pregnancy loss. WARNINGS:
Keep out of reach of children. Not for human use. Wash hands after use. Do not empty capsule contents and do not attempt to divide the capsules. Do not handle the capsules if pregnant or if trying to conceive. Trilostane is associated with teratogenic effects and early pregnancy loss in laboratory animals. In the event of accidental ingestion/overdose, seek medical advice immediately and take the labeled container with you.
Hypoadrenocorticism can develop at any dose of VETORYL Capsules. In some cases, it may take months for adrenal function to return and some dogs never regain adequate adrenal function. A small percentage of dogs may develop corticosteroid withdrawal syndrome within 10 days of starting treatment. This phenomenon results from acute withdrawal of circulating glucocorticoids clinical signs include weakness, lethargy, anorexia, and weight loss. The use of VETORYL Capsules will not affect the adrenal tumor itself. Adrenalectomy should be considered as an option for cases that are good surgical candidates. The safe use of this drug has not been evaluated in lactating dogs and males intended for breeding.
For a copy of the Material Safety Data Sheet MSDS, or to report adverse reactions, call Dechra Veterinary Products at 866 933-2472. INFORMATION FOR DOG OWNERS: Owners should be aware that the most common adverse reactions may include: an unexpected decrease in appetite, vomiting, diarrhea, or lethargy and should receive the Client Information Sheet with the prescription. Owners should be informed that control of hyperadrenocorticism should result in resolution of polyphagia, polyuria and polydipsia. Serious adverse reactions associated with this drug can occur without warning and in rare situations result in death see ADVERSE REACTIONS. Owners should be advised to discontinue VETORYL Capsules and contact their veterinarian immediately if signs of intolerance are observed. Owners should be advised of the importance of periodic follow-up for all dogs during administration of VETORYL Capsules.
STORAGE INFORMATION: Store at controlled room temperature 25°C 77°F with excursions between 15°-30°C 59°-86°F permitted.
HOW SUPPLIED: VETORYL Capsules are available in 10, 30 and 60 mg strengths, packaged in aluminum foil blister cards of 10 capsules, with 3 cards per carton.
APPROVED BY FDA. Distributed by: Dechra Veterinary Products, 7015 College Boulevard, Suite 525, Overland Park, KS 66211 VETORYL is a trademark of Dechra Ltd Vetoryl is a registered trademark of Dechra Veterinary Products. The information provided on this website is for educational purposes only and is intended to be a supplement to, and not a substitute for, the expertise and professional judgment of your veterinarian. We reference Dechra as the source for our information, you may research this product further at the Dechra webpage: http://www.dechra-us.com/files/dechraUSA/downloads/Product%20inserts/Vetoryl.pdf You should always consult your own veterinarian for specific advice concerning the diagnosis, and treatment of your pet. As stated the information provided is for educational purposes to aid you in purchasing your pet's medication, it is not a substitute for a veterinary exam, nor does this information suggest that this medication will be tolerated by your pet or that your pet will not experience side effects.
Note: Any trademarks are the property of their respective companies.